Caribou appoints Tim Kelly as CTO; plans CB-010 pivotal trial by YE 2024, cash into Q4 2025

Caribou Biosciences, Inc.

Tim Kelly appointed CTO; previously CEO of Oxford Biomedica Solutions, led technical ops at Sarepta, Shire, and Biogen.
$396.7M cash, cash equivalents, and marketable securities as of Sep 30, 2023; expected runway into Q4 2025.
CB-010: initial dose expansion data from ANTLER trial and RP2D expected Q2 2024; Phase 3 pivotal in 2L LBCL by YE 2024.
CB-011: initial dose escalation data from CaMMouflage trial expected by YE 2024.
CB-012: patient enrollment in AMpLify Phase 1 trial for r/r AML expected to initiate H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.